The commercial landscape for GLP-1 products is very different than for other pharmaceutical products. Demand is extremely high given the prevalence of obesity, direct-to-patient sales through social media and other channels, and public interest magnified by celebrity endorsement. When these factors overlap, pharmacovigilance (PV) activity increases quickly—and not always in predictable ways. These products are […]